News | Artificial Intelligence | October 18, 2019

MaxQ AI's Intracranial Hemorrhage Software to be Integrated on Philips CT Systems

MaxQ AI’s Accipio ICH and stroke software will be integrated on Philips CT systems and will be available to hospitals and radiology departments throughout the U.S. and EU

MaxQ AI's Intracranial Hemorrhage Software to be Integrated on Philips CT Systems

October 18, 2019 — Medical diagnostic artificial intelligence (AI) company MaxQ AI announced that its Accipio intracranial hemorrhage (ICH) and stroke software will be integrated on Philips’ computed tomography (CT) systems. The integration of Accipio’s AI-powered solutions into Philips CT systems will support the detection of ICH to augment caregivers in identifying and prioritizing patients suffering from stroke, traumatic brain injury, head trauma and other life-threatening conditions.

MaxQ AI’s Accipio ICH and Stroke Platform utilizes deep learning technologies to analyze medical imaging data such as non-contrast head CT images. The results provide deep clinical insight and actionable data in minutes that will enable physicians across the world to make faster assessments in any location, at any time. Accipio Ix enables automatic identification and prioritization of non-contrast head CT images with suspected ICH. Accipio Ax provides automatic slice-level annotation of suspected ICH. Both Accipio Ix and Ax are U.S. Food and Drug Administration (FDA)-cleared and CE approved.

The Accipio platform will be available with new Philips CT systems and as an upgrade to previously installed Philips CT systems throughout U.S. and EU markets. The first deployments are expected to take place in 2020.

The integration with Philips is MaxQ AI’s second such agreement in 2019 following a similar deal with GE Healthcare in January. The company announced its first distribution agreement with Samsung NeuroLogica in November 2018, shortly after Accipio IX received FDA clearance. 

Read the article “MaxQ AI Receives FDA Clearance for Accipio Ix Intracranial Hemorrhage Platform“

MaxQ AI will be demonstrating the company’s full suite of Accipio solutions during the upcoming Radiological Society of North America (RSNA) 2019 Annual Meeting, Dec. 1-6 in Chicago. Accipio will also be on display at the Philips exhibit.

For more information: www.maxq.ai, www.usa.philips.com/healthcare

Related Content

MaxQ AI's Accipio Software Integrated to GE's Smart Subscription Platform

NeuroLogica and MaxQ AI Announce Distribution Agreement

VIDEO: How Artificial Intelligence Can Detect Brain Bleeds

Related Content

Infervision's newly FDA approved CT lung AI application sets a new standard
News | Artificial Intelligence | July 10, 2020
July 10, 2020 — Infervision announced U.S.
Artificial intelligence (AI)-assisted software was used to identify inflammatory tissues in lung and automatically segment inflammatory lesions. Three-dimensional image shows regions of COVID-19 pneumonia in lung through AI postprocessing. Image courtesy of the American Journal of Roentgenology (AJR)

Artificial intelligence (AI)-assisted software was used to identify inflammatory tissues in lung and automatically segment inflammatory lesions. Three-dimensional image shows regions of COVID-19 pneumonia in lung through AI postprocessing. Image courtesy of the American Journal of Roentgenology (AJR)

News | Coronavirus (COVID-19) | July 10, 2020
July 10, 2020 — An open-access Ameri
A lung CT of a COVID-19 patient, showing ground-glass opacities in the lung from COVID pneumonia. Image courtesy of John Kim.

A lung CT of a COVID-19 patient, showing ground-glass opacities in the lung from COVID pneumonia. Image courtesy of John Kim.

News | Coronavirus (COVID-19) | July 09, 2020
July 9, 2020 — With increased lung CT exam paradigms being used in the current...

Image courtesy of GE Healthcare

Feature | Mobile C-Arms | July 08, 2020 | By Melinda Taschetta-Millane
Moblie C-arms have seen several advances over the past de
At the American Association of Physicists in Medicine (AAPM) 2019 meeting, new artificial intelligence (AI) software to assist with radiotherapy treatment planning systems was highlighted. The goal of the AI-based systems is to save staff time, while still allowing clinicians to do the final patient review. 
Feature | Treatment Planning | July 08, 2020 | By Melinda Taschetta-Millane
At the American Association of Physicists in Medicine (AAPM) 201
This data represents wave 2 of a QuickPoLL survey conducted in partnership with an imagePRO panel created by The MarkeTech Group (TMTG), regarding the effects of COVID-19 on their business

Getty Images

Feature | Coronavirus (COVID-19) | July 01, 2020 | By Melinda Taschetta-Millane
A 3-D ultrasound system provides an effective, noninvasive way to estimate blood flow that retains its accuracy across different equipment, operators and facilities, according to a study published in the journal Radiology.

Volume flow as a function of color flow gain (at a single testing site). For each row the color flow c-plane and the computed volume flow are shown as a function of color flow gain. The c-plane is shown for four representative gain levels, whereas the computed volume flow is shown for 12–17 steps across the available gain settings. Flow was computed with (solid circles on the graphs) and without (hollow circles on the graphs) partial volume correction. Partial volume correction accounts for pixels that are only partially inside the lumen. Therefore, high gain (ie, blooming) does not result in overestimation of flow. Systems 1 and 2 converge to true flow after the lumen is filled with color pixel. System 3 is nearly constant regarding gain and underestimates the flow by approximately 17%. Shown are mean flow estimated from 20 volumes, and the error bars show standard deviation. Image courtesy of the journal Radiology

News | Ultrasound Imaging | July 01, 2020
July 1, 2020 — A 3-D ultrasound
R2* maps of healthy control participants and participants with Alzheimer disease. R2* maps are windowed between 10 and 50 sec21. Differences in iron concentration in basal ganglia are too small to allow visual separation between patients with Alzheimer disease and control participants, and iron levels strongly depend on anatomic structure and subject age. Image courtesy of Radiological Society of North America

R2* maps of healthy control participants and participants with Alzheimer disease. R2* maps are windowed between 10 and 50 sec21. Differences in iron concentration in basal ganglia are too small to allow visual separation between patients with Alzheimer disease and control participants, and iron levels strongly depend on anatomic structure and subject age. Image courtesy of Radiological Society of North America

News | Magnetic Resonance Imaging (MRI) | July 01, 2020
July 1, 2020 — Researchers using magnetic...